3SBIO's stock price soared 6.00% at market open on Monday, driven by positive clinical data presentations and a major licensing agreement.

The biopharmaceutical company presented impressive clinical data for its core pipeline asset SSGJ-707, a PD-1/VEGF bispecific antibody, at the ASCO Annual Meeting. In a Phase II study for advanced non-small cell lung cancer, SSGJ-707 monotherapy demonstrated a confirmed objective response rate of 67.6% with median progression-free survival of 12.4 months. For first-line endometrial cancer in combination with chemotherapy, confirmed response rates reached 85.7% and 80.0%, respectively.

Additionally, 3SBIO recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately $6.05 billion, including a $1.25 billion upfront payment, validating the asset's global commercial potential. The broader biotechnology sector also showed strength, providing additional positive momentum for 3SBIO's shares.